Exploratory Study on Global Reflexology in Sickle Cell Disease
Sickle cell disease (or sickle cell anemia) is the most common genetic disease in France with 586 children screened in 2019. This chronic disease is characterized by the presence of abnormal Hemoglobin (Hb) S and a deformation of the red blood cells which take the elongated shape of a sickle and become more rigid and m
| Condition(s) | Sickle Cell Disease (SCD) |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Sickle cell disease (or sickle cell anemia) is the most common genetic disease in France with 586 children screened in 2019. This chronic disease is characterized by the presence of abnormal Hemoglobin (Hb) S and a deformation of the red blood cells which take the elongated shape of a sickle and become more rigid and more fragile. Sickle cell disease manifests itself among other things by very painful vaso-occlusive crises (VOC) and for some chronic pain. Their management is an emergency and often requires hospitalization. Despite analgesic treatment, some patients have persistent pain. In 2013, a childcare assistant trained in Canadian global reflexology EMC offered reflexology sessions to 12 sickle cell patients. She observed a relief in all patients with a decrease in the pain score in |
| Who can participate | Inclusion Criteria: * Patient under 18 years of age * Patient suffering from sickle cell disease * Patient hospitalized in the UHCD or USC unit of the Women\'s Mother and Child Hospital of the Hospices Civils de Lyon for the management of a CVO * Informed consent signed by at least one holder of parental authority * Collection of the patient\'s assent as soon as his age allows it. Exclusion Criteria: * Patient with PCA (Patient Controlled Analgesia) * Patient with NCA (Nurse Controlled Analgesia) * Patient not affiliated to a social security scheme or beneficiaries of a similar scheme. |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Hospices Civils de Lyon |
| Locations | Bron, France |
| Start date | 2025-06-30 |
| NCT ID | NCT06619197 |
| Official listing | https://clinicaltrials.gov/study/NCT06619197 |